Zydus Cadila and Bayer have announced the extension of their ten-year long joint venture by three more years. The companies will continue to focus on core therapies including cardiovascular diseases, diabetes, women’s health, ophthalmology and oncology, in India.
Zydus Cadila has announced the extension of its joint venture with Bayer AG by three years from June 2021. The companies first formed Bayer Zydus Pharma in 2011 for the sales and marketing of pharmaceutical products in India, with headquarters in Mumbai.
The aim of the joint venture is “to address the unmet healthcare needs of patients in India by providing best-in-class...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
